Yoram Palti

Dr. Yoram Palti

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2017 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
MGMoshe Giladi
Moshe Giladi
MMMijal Munster
Mijal Munster
RSRosa Shnaiderman
Rosa Shnaiderman
TVTali Voloshin
Tali Voloshin
YPYaara Porat
Yaara Porat
YPYoram Palti
Yoram Palti
Tumor Treating Fields (TTFields) are an anti-neoplastic treatment modality delivered via application of alternating electric fields using insulated transducer arrays placed directly on the skin in the region surrounding the tumor. A Phase 3 clinical trial has demonstrated the effectiveness of continuous TTFields application in patients with glioblastoma during maintenance treatment with Temozolomide. The goal of this study was to evaluate the efficacy of combining TTFields with radiation treatment (RT) in glioma cells. We also examined the effect of TTFields transducer arrays on RT distribution in a phantom model and the impact on rat skin toxicity. The efficacy of TTFields application after induction of DNA damage by RT or bleomycin was tested in U-118 MG and LN-18 glioma cells. The alkaline comet assay was used to measure repair of DNA lesions. Repair of DNA double strand breaks (DSBs) were assessed by analyzing γH2AX or Rad51 foci. DNA damage and repair signaled by the activation pattern of phospho-ATM (pS1981) and phospho-DNA-PKcs (pS2056) was evaluated by immunoblotting. The absorption of the RT energy by transducer arrays was measured by applying RT through arrays placed on a solid-state phantom. Skin toxicities were tested in rats irradiated daily through the arrays with 2Gy (total dose of 20Gy). TTFields synergistically enhanced the efficacy of RT in glioma cells. Application of TTFields to irradiated cells impaired repair of irradiation- or chemically-induced DNA damage, possibly by blocking homologous recombination repair. Transducer arrays presence caused a minor reduction in RT intensity at 20 mm and 60 mm below the arrays, but led to a significant increase in RT dosage at the phantom surface jeopardizing the “skin sparing effect”. Nevertheless, transducer arrays placed on the rat skin during RT did not lead to additional skin reactions. Administration of TTFields after RT increases glioma cells treatment efficacy possibly by inhibition of DNA damage repair. These preclinical results support the application of TTFields therapy immediately after RT as a viable regimen to enhance RT outcome. Phantom measurements and animal models imply that it may be possible to leave the transducer arrays in place during RT without increasing skin toxicities.

17 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
TVTali Voloshin
Tali Voloshin
RSRosa Shnaiderman
Rosa Shnaiderman
AVAlexandra Volodin
Alexandra Volodin
RSReuben Ruby Shamir
Reuben Ruby Shamir
NKNoa Kaynan
Noa Kaynan
YPYoram Palti
Yoram Palti
Tumor Treating Fields (TTFields) are noninvasive, alternating electric fields within the intermediate frequency range (100–300 kHz) that are utilized as an antimitotic cancer treatment. TTFields are loco-regionally delivered to the tumor region through 2 pairs of transducer arrays placed on the skin. This novel treatment modality has been FDA-approved for use in patients with glioblastoma and malignant pleural mesothelioma based on clinical trial data demonstrating efficacy and safety; and is currently under investigation in other types of solid tumors. TTFields were shown to induce an anti-mitotic effect by exerting bi-directional forces on highly polar intracellular elements, such as tubulin and septin molecules, eliciting abnormal microtubule polymerization during spindle formation as well as aberrant cleavage furrow formation. Previous studies have demonstrated that TTFields inhibit metastatic properties in cancer cells. However, the consequences of TTFields application on cytoskeleton dynamics remain undetermined. In this study, methods utilized in combination to study the effects of TTFields on cancer cell motility through regulation of microtubule and actin dynamics included confocal microscopy, computational tools, and biochemical analyses. Mechanisms by which TTFields treatment disrupted cellular polarity were (1) interference with microtubule assembly and directionality; (2) altered regulation of Guanine nucleotide exchange factor-H1 (GEF-H1), Ras homolog family member A (RhoA), and Rho-associated coiled-coil kinase (ROCK) activity; and (3) induced formation of radial protrusions of peripheral actin filaments and focal adhesions. Overall, these data identified discrete effects of TTFields that disrupt processes crucial for cancer cell motility.

1 January 2014 in Pancreatology
Verified
Journal Article
Closed access
MGMoshe Giladi
Moshe Giladi
RSRosa S. Schneiderman
Rosa S. Schneiderman
YPYaara Porat
Yaara Porat
MMMijal Munster
Mijal Munster
AIAviran Itzhaki
Aviran Itzhaki
YPYoram Palti
Yoram Palti

Verified
Journal Article
Open access
PDF file
YBYiftah Barsheshet
Yiftah Barsheshet
TVTali Voloshin
Tali Voloshin
BBBoris Brant
Boris Brant
GCGadi Cohen
Gadi Cohen
LKLilach Koren
Lilach Koren
YPYoram Palti
Yoram Palti
Tumor Treating Fields (TTFields) are electric fields that exert physical forces to disrupt cellular processes critical for cancer cell viability and tumor progression. TTFields induce anti-mitotic effects through the disruption of the mitotic spindle and abnormal chromosome segregation, which trigger several forms of cell death, including immunogenic cell death (ICD). The efficacy of TTFields concomitant with anti-programmed death-1 (anti-PD-1) treatment was previously shown in vivo and is currently under clinical investigation. Here, the potential of TTFields concomitant with anti- PD-1/anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) or anti-programmed death-ligand 1 (anti-PD-L1) immune checkpoint inhibitors (ICI) to improve therapeutic efficacy was examined in lung tumor-bearing mice. Increased circulating levels of high mobility group box 1 protein (HMGB1) and elevated intratumoral levels of phosphorylated eukaryotic translation initiation factor 2α (p-eIF2α) were found in the TTFields-treated mice, indicative of ICD induction. The concomitant application of TTFields and ICI led to a significant decrease in tumor volume as compared to all other groups. In addition, significant increases in the number of tumor-infiltrating immune cells, specifically cytotoxic T-cells, were observed in the TTFields plus anti-PD-1/anti-CTLA-4 or anti-PD-L1 groups. Correspondingly, cytotoxic T-cells isolated from these tumors showed higher levels of IFN-γ production. Collectively, these results suggest that TTFields have an immunoactivating role that may be leveraged for concomitant treatment with ICI to achieve better tumor control by enhancing antitumor immunity.

15 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SDShiri Davidi
Shiri Davidi
SJSara Jacobovitch
Sara Jacobovitch
ASAnna Shteingauz
Anna Shteingauz
AMAntonia Martinez-Conde
Antonia Martinez-Conde
OBOri Braten
Ori Braten
YPYoram Palti
Yoram Palti
Hepatocellular carcinoma (HCC), a highly aggressive liver cancer, is a leading cause of cancer-related death. Tumor Treating Fields (TTFields) are electric fields that exert antimitotic effects on cancerous cells. The aims of the current research were to test the efficacy of TTFields in HCC, explore the underlying mechanisms, and investigate the possible combination of TTFields with sorafenib, one of the few front-line treatments for patients with advanced HCC. HepG2 and Huh-7D12 human HCC cell lines were treated with TTFields at various frequencies to determine the optimal frequency eliciting maximal cell count reduction. Clonogenic, apoptotic effects, and autophagy induction were measured. The efficacy of TTFields alone and with concomitant sorafenib was tested in cell cultures and in an orthotopic N1S1 rat model. Tumor volume was examined at the beginning and following 5 days of treatment. At study cessation, tumors were weighed and examined by immunohistochemistry to assess autophagy and apoptosis. TTFields were found in vitro to exert maximal effect at 150 kHz, reducing cell count and colony formation, increasing apoptosis and autophagy, and augmenting the effects of sorafenib. In animals, TTFields concomitant with sorafenib reduced tumor weight and volume fold change, and increased cases of stable disease following treatment versus TTFields or sorafenib alone. While each treatment alone elevated levels of autophagy relative to control, TTFields concomitant with sorafenib induced a significant increase versus control in tumor ER stress and apoptosis levels, demonstrating increased stress under the multimodal treatment. Overall, TTFields treatment demonstrated efficacy and enhanced the effects of sorafenib for the treatment of HCC in vitro and in vivo, via a mechanism involving induction of autophagy.

1 November 2016 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
RSRoger Stupp
Roger Stupp
Ahmed IdbaihAhmed Idbaih
Ahmed Idbaih
DSDavid M. Steinberg
David M. Steinberg
WRWilliam Read
William Read
STSteven Toms
Steven Toms
ZRZvi Ram
Zvi Ram
Tumor Treating Fields (TTFields) is an established, frequency-tuned, anti-mitotic, physical treatment modality that acts in metaphase, anaphase and telophase. TTFields are delivered to the brain by a patient operated, portable medical device (Optune™, Novocure Ltd.). An international, multicenter, prospective, randomized phase 3 trial (EF-14) was initiated in 2009 to test the efficacy and safety of combining TTFields with temozlomide (TMZ) compared to TMZ alone following radiation therapy with adjuvant TMZ in patients with newly diagnosed GBM. Results of a protocol pre-specified successful interim analysis on the first 315 patients randomized has been reported (Stupp et al. JAMA 2015). Here we report the main outcomes of all 695 patients enrolled with a mature minimum follow-up of 18 month (median follow-up 36 months) for all patients (Range 19–80 months). Within 7 weeks after the end of TMZ/RT and stratification for extent of resection and MGMT status patients were randomized (at a 1:2 ratio) to either standard adjuvant TMZ alone (150–200 mg/m2/d x 5d) or TMZ and continuous administration of TTFields. Eligible patients had a newly diagnosed GBM, non-progressive after concomitant chemoradiotherapy, a performance status of ≥70%, and adequate hematological, liver and renal function. The primary endpoint of the study is progression free survival (PFS) as determined by blinded central radiology review; overall survival (OS) is a powered secondary endpoint. A total of 695 patients were randomized from 7/2009 – 11/2014. Patient characteristics are balanced, median age was 56 years (range 19–83), 87 % had undergone prior tumor resection and 13 % a biopsy only. 37% of tumors were MGMT methylated. Median time from end of radiotherapy to randomization was 37 days. The median number of adjuvant (maintenance) TMZ cycles 6 and 5 cycles, for TTFields/TMZ and TMZ alone, respectively. All analyses are intent-to-treat. The median progression-free survival was 6.7 months (95%CI 6.1–8.1) for the patients treated with TTFields/TMZ versus 4.0 months (CI 3.8 – 4.3) for TMZ alone (hazard ratio 0.63, p<0.00005). Median overall survival from randomization is 21 months versus 16 months for the TTFields/TMZ and TMZ alone, respectively, with a hazard ratio of 0.65 (CI 0.54–0.79), p<0.00062. The respective 2, 3 and 4-year survival rates are 43% (CI 38–47%) and 30% (CI 24–37), 24% (CI 19–29) and 16% (CI 11–23), 17% (CI 13–23) and 10% (CI 6–18); p<0.05 for all time points. This first and mature analysis of the full cohort of all randomized patients confirms and improves upon the superior results of TTFields/TMZ compared to TMZ alone seen in the trial’s interim analysis. The addition of TTFields to maintenance TMZ significantly extends both median and long term survival of patients with glioblastoma. The magnitude of survival benefit seen is equivalent to that seen for addition of TMZ to radiation which established TMZ as the standard of care for 1st line glioblastoma over a decade ago.